Oculis Holding AG (OCS) Common Equity (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Common Equity came in at $251.1 million in Q1 2026, up 38.83% year-on-year from $180.9 million in Q1 2025, and up 2.37% quarter-over-quarter from $245.3 million in Q4 2025.
Oculis Holding AG (OCS) Common Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Common Equity history runs 6 years deep, the most recent figure standing at $251.1 million for Q1 2026.
- On a quarterly basis, Common Equity rose 38.83% year-over-year to $251.1 million in Q1 2026; TTM through Mar 2026 was $251.1 million, a 38.83% increase from a year earlier, with the FY2025 full-year figure at $236.5 million, up 183.51% from the prior year.
- Common Equity grew to $251.1 million in Q1 2026 per OCS's latest filing, from $245.3 million in the prior quarter.
- Across five years, Common Equity topped out at $251.1 million in Q1 2026 and bottomed at -$101.7 million in Q4 2022.
- The 5-year median for Common Equity is $124.8 million (2024), against an average of $128.9 million.
- Across the five-year window, Common Equity sank 53.87% in 2022 and surged 203.88% in 2023, its largest moves.
- Year by year, Common Equity stood at -$101.7 million in 2022, then jumped by 203.88% to $105.7 million in 2023, then declined by 20.72% to $83.8 million in 2024, then surged by 192.85% to $245.3 million in 2025, then increased by 2.37% to $251.1 million in 2026.
- Per Business Quant, the three latest OCS Common Equity figures stand at $251.1 million (Q1 2026), $245.3 million (Q4 2025), and $163.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -98.34 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 14.38 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 4.76 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.50 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.12 Mn |
| Dec 31, 2025 | 245.32 Mn |
| Sep 30, 2025 | 163.26 Mn |
| Jun 30, 2025 | 172.84 Mn |
| Mar 31, 2025 | 180.88 Mn |
| Dec 31, 2024 | 83.77 Mn |
| Sep 30, 2024 | 109.91 Mn |
| Jun 30, 2024 | 124.76 Mn |
| Mar 31, 2024 | 90.55 Mn |
| Dec 31, 2023 | 105.66 Mn |
| Sep 30, 2023 | 119.56 Mn |
| Jun 30, 2023 | 130.34 Mn |
| Dec 31, 2022 | -101.72 Mn |
| Dec 31, 2021 | -66.11 Mn |